04-JUL-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     4043 376 185 79 22 8 02/06/2019 475 184
Screened at PD     1518 237 129 55 15 7      
Pre-Screened prior to PD     2501 121 49 21 6 1      
Treatment-naive     24 18 7 3 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     535 28 15 5 1 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2216 300 161 74 21 7      
Screened at PD     1289 236 132 61 16 6      
Pre-Screened prior to PD     845 43 19 9 3 1      
Treatment-naive     24 18 8 3 1 0      
After PD on a Lung_MAP Sub-Study     58 3 2 1 1 0      
 
Sub-Study Assignments (open studies only)
S1800E     407 261 139 66 18 6      
S1900G     39 8 6 4 2 1      
S1900J     18 6 3 0 0 0      
S1900K     42 25 13 4 1 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     646 135 79 34 14 2      
Initial sub-study registrations     633 134 78 33 13 1      
Subsequent sub-study registrations     13 1 1 1 1 1      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 112 108 63 27 11 2 05/22/2025 350 116
Docetaxel plus Ramucirumab Y   58 56 33 15 5 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   54 52 30 12 6 2      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   44 27 6 4 2 1 0 05/05/2023 338 107
Capmatinib + Osimertinib + Ramucirumab Y   15 4 2 1 1 0      
Capmatinib + Osimertinib Y   12 2 2 1 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 2 1 0 0 0 11/19/2024 282 84
Amivantamab Hyaluronidase Y   4 2 1 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 29 19 11 5 2 0 08/08/2024 270 89
Tepotinib + Ramucirumab Y   20 13 9 4 2 0      
Tepotinib Y   9 6 2 1 0 0